Mobile

An Open-label Randomized Phase II Study of Panitumumab Plus Oral Capecitabine and Infusional Oxaliplatin (XELOX) or XELOX alone for Second-line Treatment of Patients with Metastatic Clororectal Cancer...

Mise à jour : Il y a 4 ans
Référence : EUCTR2007-004866-42

An Open-label Randomized Phase II Study of Panitumumab Plus Oral Capecitabine and Infusional Oxaliplatin (XELOX) or XELOX alone for Second-line Treatment of Patients with Metastatic Clororectal Cancer (Voxel-Study)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To assess the differences in progression-free survival at 6 months in subjects with KRAS wild-type metastatic colorectal cancer receiving second line treatment (after failure of a previous irinotecan and 5FU based regimen) with panitumumab plus XELOX compared to the treatment with XELOX alone, without major safety problems

Critère d'inclusion

  • metastatic colorectal cancer (mCRC)

Liens